Idenix reports progress on two hepatitis C candidates
This article was originally published in Scrip
Executive Summary
Cambridge, Massachusetts-based Idenix Pharmaceuticals has reported positive data from both an interim analysis of a Phase II study of its drug candidate for hepatitis C virus (HCV), IDX184, and a three-day proof-of-concept trial for another HCV candidate, IDX719. The company said it would begin a combination study of the two products by the end of the year.